Viatris Launches Hulio (biosimilar- adalimumab) in Canada
Shots:
- Health Canada has approved Hulio- a biosimilar referencing AbbVie’s Humira (adalimumab)- which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab indications
- The approval was based on an analytical- pre/ clinical program. Fujifilm Kyowa Kirin conducted a P-III ARABESC study that demonstrated no differences in terms of safety- efficacy- and immunogenicity compared to its reference product in patients with RA
- Fujifilm Kyowa Kirin and Viatris aims to expand patient access to more affordable biosimilar medicines across the globe- including in Canada
Ref: Newswire Canada | Image: Vaitris
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com